Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Clinical Trial Size in Orphan and Rare Diseases

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Dec 03, 2023 8:06pm

121 Views

Post# 35766280

RE:RE:RE:RE:RE:RE:Clinical Trial Size in Orphan and Rare Diseases

Should read .... "And ... Accelerated Approval in the context of an adaptive clinical trial involves a seamless transition from a Phase 2 trial to a Phase 3 confirmatory trial ( traditionally known as a Phase 4 post-marketing study). "

<< Previous

Bullboard Posts

Next >>

High-growth stock Happy Belly opens first Rosie's Burgers in Alberta